Liminatus Pharma Plans Phase 1 Trial for IBA101, a Next-Generation CD47 Blocking Antibody

Liminatus Pharma plans to initiate a Phase 1 clinical trial for IBA101, a CD47-blocking antibody designed to enhance immune surveillance and complement PD-1/PD-L1 therapies. The trial will evaluate safety, tolerability, and pharmacokinetics, as well as combinations with PD-1/PD-L1 inhibitors. Lung cancer is the initial focus, and the company anticipates engaging with regulatory authorities and targeting readiness to advance the program.